NxStage Medical to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference on February 7, 2008

Friday February 1, 2008

LAWRENCE, Mass., Feb. 1 /PRNewswire-FirstCall/ — NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced that Jeffrey H. Burbank, Chief Executive Officer, will participate in the Merrill Lynch Pharmaceutical, Biotechnology & Medical Device Conference. Mr. Burbank is scheduled to present an overview of the Company at 8:40 a.m. Eastern Time on Thursday, February 7, 2008 at The Grand Hyatt at Park Avenue in New York.

To listen to the audio web cast of the presentation during the event, please visit: http://www.nxstage.com and click on ‘Investor Information.’ A replay will be available for 14 days immediately following the live presentation.

About NxStage Medical

NxStage Medical, Inc. (Nasdaq: NXTM) is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative products for the treatment of end-stage renal disease, or ESRD, and acute kidney failure. For more information on NxStage and its products, please visit the Company’s website at http://www.nxstage.com.

Forward-Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words anticipate, believe, expect, estimate, plan, and similar expressions are generally intended to identify forward-looking statements. The forward-looking statements in this release include NxStage’s plan to present at the Merrill Lynch Global Pharmaceutical & Medical Device Conference. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors including, but not limited to, unexpected difficulty in getting to the conference and other factors that are discussed in NxStage’s filings with the Securities and Exchange Commission, including the Quarterly Report on Form 10-Q for the quarter ended September 30, 2007. NxStage is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward- looking statements, whether as a result of new information, future events or otherwise.

SOURCE NxStage Medical, Inc.

Contact:
Kristen K. Sheppard, Esq.
Vice President, Investor Relations
NxStage Medical Inc. (NXTM)
978/332-5923
Web site: http://www.nxstage.com